SCHEMBL1606587

SCHEMBL1606587

C/C=C/CN(C)CC(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHF8 Q9UPP1 3/20 0.35
KDM2A Q9Y2K7 3/20 0.35
KDM6B O15054 1/20 0.35
KDM5C P41229 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
TDP1 Q9NUW8 2/20 0.33
MVD P53602 1/20 0.33
EYA2 O00167 1/20 0.33
APP P05067 1/20 0.33
ACE P12821 1/20 0.33
BHMT Q93088 1/20 0.33
ALOX15 P16050 2/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
CHRM2 P08172 1/20 0.32
ADRA2A P08913 1/20 0.32
TSHR P16473 1/20 0.32
DRD1 P21728 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL711366 0.81 TDP1 (0.48) PHF8KDM2AKDM6BKDM5CEGLN1
SCHEMBL711365 0.81 TDP1 (0.48) PHF8KDM2AKDM6BKDM5CEGLN1
SCHEMBL18072723 0.77 BHMT (0.37) TDP1MVDEYA2APPACE
SCHEMBL3933125 0.76
SCHEMBL21408120 0.76 GRIK1 (0.32) PHF8KDM2AKDM6BKDM5CEGLN1
SCHEMBL3084567 0.75 MVD (0.40) MVD
SCHEMBL461717 0.74
SCHEMBL516493 0.74 TSHR (0.32) TSHR
SCHEMBL22061 0.74 TDP1 (0.47) PHF8KDM2AKDM6BKDM5CEGLN1
SCHEMBL16665100 0.74 CHRNB2 (0.47) BHMTHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12566161-B2 Methods and consumer products for detecting a metabolite KIMBERLY-CLARK WORLDWIDE, INC. (US) 2026-03-03 US claimed
US-20230400438-A1 METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE KIMBERLY-CLARK WORLDWIDE, INC. 2023-12-14 US claimed
CN-116490772-A Method and consumer product for detecting metabolites 金伯利-克拉克环球有限公司 2023-07-25 CN claimed
CN-115754300-A Plasma metabolism markers for predicting non-proliferative DR occurrence risk, application thereof and construction method of scoring model 深圳市人民医院 2023-03-07 CN claimed
WO-2022190030-A1 A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES AVACA PHARMA PRIVATE LIMITED (IN) 2022-09-15 WO claimed
WO-2022125056-A1 METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE KIMBERLY-CLARK WORLDWIDE, INC. (US) 2022-06-16 WO claimed
CN-106537145-B Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment 麦特博隆股份有限公司 2020-08-25 CN claimed
CN-108572251-B Small molecule marker for early stage of cirrhosis and application thereof 中国科学院昆明动物研究所 2020-01-17 CN claimed
US-12622876-B2 Methods of suppressing delivery of exosomes to liver and spleen LONZA SALES AG (CH) 2026-05-12 US disclosed
US-12578322-B2 Methods and consumer products for detecting a metabolite KIMBERLY-CLARK WORLDWIDE, INC. (US) 2026-03-17 US disclosed
US-12566161-B2 Methods and consumer products for detecting a metabolite KIMBERLY-CLARK WORLDWIDE, INC. (US) 2026-03-03 US disclosed
US-12566161-B2 Methods and consumer products for detecting a metabolite KIMBERLY-CLARK WORLDWIDE, INC. (US) 2026-03-03 US disclosed
US-12050228-B2 Automated sample quality assessment METABOLON, INC. (US) 2024-07-30 US disclosed
US-20230417734-A1 METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE KIMBERLY-CLARK WORLDWIDE, INC. 2023-12-28 US disclosed
US-20150306212-A1 SYNTHETIC MEMBRANE-RECEIVER COMPLEXES FLAGSHIP VENTURES MANAGEMENT, INC. 2015-10-29 US disclosed
WO-2015157407-A1 SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT METABOLON, INC. (US) 2015-10-15 WO disclosed
WO-2015153102-A1 METHODS AND COMPOSITIONS FOR IMMUNOMODULATION RUBIUS THERAPEUTICS, INC. (US) 2015-10-08 WO disclosed
US-20150182588-A1 SYNTHETIC MEMBRANE-RECEIVER COMPLEXES FLAGSHIP VENTURES MANAGEMENT, INC. 2015-07-02 US disclosed
US-20150065366-A1 Biomarkers for Bladder Cancer and Methods Using the Same METABOLON, INC. 2015-03-05 US disclosed
US-20110081675-A1 Metabolic Biomarkers Of Drug-Induced Cardiotoxicity WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622876-B2 Methods of suppressing delivery of exosomes to liver and spleen EXOSC10, EXOSC5, EXOSC4 PHF8 3484/4885KDM2A 2393/4885KDM6B 1518/4885
US-12566161-B2 Methods and consumer products for detecting a metabolite SLC6A6, SLC7A11, CTH PHF8 3969/4885KDM2A 4046/4885KDM6B 1660/4885
US-12578322-B2 Methods and consumer products for detecting a metabolite SHBG, OXGR1, OGG1 PHF8 2749/4885KDM2A 1307/4885KDM6B 1245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.